# Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

> **NCT05720455** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 203 (actual)

## Conditions studied

- Rhinitis Allergic

## Interventions

- **DRUG:** Fexofenadine HCL and pseudoephedrine HCL

## Key facts

- **NCT ID:** NCT05720455
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-15
- **Primary completion:** 2025-12-05
- **Final completion:** 2025-12-05
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720455, "Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05720455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*